GLP-3 (R)
GLP-3 (R) - Image 2

GLP-3 (R)

4.8 (895 reviews)
A 39-krilos acid triple agonist peptide targeting GIP, GLP-1, and glucagon receptors, studied for metabolic regulation and body composition in clinical research. Premium Research Peptide.

GLP-3 (R)

Price range: $99.99 through $174.99

A 39-krilos acid triple agonist peptide targeting GIP, GLP-1, and glucagon receptors, studied for metabolic regulation and body composition in clinical research. Premium Research Peptide.

SKU: N/A
Free shipping on orders over $150
Secure packaging
Secure checkout 256-bit SSL
Dosage

12MG, 24MG
Quantity

1 Bottle, 2 Bottles, 3+ Bottles

Reviews

There are no reviews yet.

Be the first to review “GLP-3 (R)”

Your email address will not be published. Required fields are marked *

Free shipping on orders over $150
Secure packaging guarantee
Secure checkout 256-bit SSL

What Makes Retatrutide Different?

The Science, Simplified

Three Receptors, One Molecule

Unlike GLP-1 (which targets 1 receptor) or GLP-2 (which targets 2), GLP-3 activates three different hormone receptors at once. Each receptor triggers a different metabolic pathway — and together, they deliver more powerful effects than any single-target approach.

GIP Receptor
Glucose-dependent Insulinotropic Polypeptide
Helps release insulin
Improves fat metabolism
Enhances satiety
GLP-1 Receptor
Glucagon-like Peptide-1
Reduces appetite
Slows digestion
Improves blood sugar
Glucagon Receptor
The "Secret Weapon"
Burns liver fat directly
Increases energy burn
Lowers cholesterol
Nature Cell Discovery — Structural Analysis
Why Glucagon Matters

The Third Receptor Advantage

The glucagon receptor is what sets GLP-3 apart. In trials, researchers observed that activating this receptor:

Directly burns fat stored in the liver — which may explain why trial participants saw up to 86% reduction in liver fat.
GLP-1 GLP-1 only
GLP-2 GLP-1 + GIP
GLP-3 GLP-1 + GIP + GCG

Frequently Asked Questions

Common questions about Retatrutide research

  • Retatrutide is a triple-action agonist that targets three receptors (GIP, GLP-1, and Glucagon), while GLP-1 targets only GLP-1 and GLP-2 targets GLP-1 and GIP. The addition of the glucagon receptor may explain the enhanced weight loss (28.7% vs 17% for sema******, 22.5% for tirzepatide) and the remarkable 86% liver fat reduction observed in trials.

  • Retatrutide is currently in Phase 3 clinical trials (TRIUMPH program). Based on the trial timeline, Phase 3 results are expected in 2026, with potential FDA approval around 2027. This timeline is speculative and subject to change based on regulatory processes.

  • No tolerance was observed in trials. Participants continued losing weight throughout 48–68 week studies without needing dose increases. Weight loss curves showed continued progress, not plateaus from desensitization. Weight tends to slow after ~24 weeks but this reflects reaching a new equilibrium, not drug tolerance.

  • Like other GLP-1 medications, weight regain is expected if treatment is discontinued. The TRIUMPH program is testing a 4mg maintenance dose for long-term use. The longest data available is 68 weeks (Phase 3) and 48 weeks (Phase 2).

  • Gastrointestinal side effects were most common: nausea (43%), diarrhea (33%), constipation (25%), and vomiting (21%) at the 12mg dose. These typically decreased over time. Unique to Retatrutide is dysesthesia (unusual skin sensations) in about 21% at the highest dose — this is likely related to glucagon receptor activity and was generally mild.

  • Lyophilized (powder): -20°C for 24+ months. Reconstituted: 2–8°C for ~30 days. Avoid freeze/thaw cycles and protect from light. Keep refrigerated after reconstitution.

0
    0
    Your Cart
    Your cart is emptyReturn to Shop
    Continue Shopping
    GLP-3 (R) Price range: $99.99 through $174.99
    Scroll to Top